Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.56 |
| ▸ | SKP1 | P63208 | 2/20 | 0.56 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591643 | 0.81 | CKS1B (0.55) | CKS1BSKP1SKP2MAPTMAP4K4 | |
| SCHEMBL23854740 | 0.80 | CKS1B (0.48) | CKS1BSKP1SKP2MAPTMAP4K4 | |
| SCHEMBL21594175 | 0.80 | CKS1B (0.58) | CKS1BSKP1SKP2MAPTMAP4K4 | |
| SCHEMBL29871883 | 0.80 | CKS1B (0.58) | CKS1BSKP1SKP2MAPTMAP4K4 | |
| SCHEMBL26034788 | 0.79 | MAPT (0.41) | CKS1BSKP1SKP2MAPTMAP4K4 | |
| SCHEMBL21591693 | 0.78 | CKS1B (0.57) | CKS1BSKP1SKP2MAPTMAP4K4 | |
| SCHEMBL30064201 | 0.76 | CKS1B (0.50) | CKS1BSKP1SKP2MAPTGPR119 | |
| SCHEMBL20046670 | 0.76 | CKS1B (0.64) | CKS1BSKP1SKP2MAPTMAP4K4 | |
| SCHEMBL13568089 | 0.75 | MAP4K4 (0.50) | CKS1BSKP1SKP2MAPTMAP4K4 | |
| SCHEMBL14614610 | 0.75 | CKS1B (0.59) | CKS1BSKP1SKP2MAPTMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | SSB, UACA, HLA-DRB1 | CKS1B 2109/4885SKP1 1909/4885SKP2 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.